Gyros Platform Chosen by Merck Millipore in Expansion of Contract Service Offerings
Merck Millipore’s BioPharma Services Organization to use Gyrolab™ workstation for immunogenicity, pharmacokinetics (PK), current cGMP testing, and fit-for-purpose biomarker assays
Gyros AB, a leader in the automation of miniaturized immunoassays, announced today that Merck Millipore’s BioPharma Services organization, the world’s leading large molecule lab, has purchased a Gyrolab™ xP workstation to expand the Company’s contract research services for the biopharmaceutical industry.
Merck Millipore is among the first contract service organizations in the United States to invest in a Gyrolab workstation. The unique microfluidic technology will allow Merck Millipore to miniaturize assays for all of the organization’s contract service programs, which include immunogenicity, pharmacokinetics (PK), and current Good Manufacturing Practice (cGMP) testing, as well as for fit-for-purpose biomarker assays.
“As a contract service organization to pharma, our reputation is founded on quality, reliability and cost-effectiveness,” said Christina Shasserre, Head of Discovery and Development Solutions for Merck Millipore. “To this end, we are continually looking for solutions that enhance our throughput and output to exceed our customers’ expectations. The Gyrolab workstation is an integral part of this equation.”
“In our evaluation of the Gyrolab xP workstation, we were particularly impressed with the system’s high level of accuracy; rapid method development and validation; and delivery of robust assays—even in 50% matrix,” said Ron Bowsher, Chief Scientist for BioPharma Services at Merck Millipore. “Incorporating Gyrolab technology into our offering will give us a competitive advantage for servicing the fields of pharmacokinetics, anti-drug antibody, and host-cell protein (HCP) testing.”
Commenting on the announcement, Erik Walldén, CEO at Gyros, said: “We see Merck Millipore’s investment as strong confirmation that our offering delivers what is important to our customers. From a company perspective, this signals a growing acceptance of our technology, and a major step in our expansion, within the US market.”
For Gyros AB
Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: email@example.com / firstname.lastname@example.org
Notes to editors:
About Gyros (www.gyros.com)
Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.
Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.
The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.